Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
3
60%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (40.0%)
N/A3 (60.0%)

Trials by Status

completed360%
active_not_recruiting120%
withdrawn120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingnot_applicable

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

NCT04685109
completednot_applicable

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

NCT04701086
completedphase_3

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

NCT02023268
completedphase_3

Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome

NCT01568593
withdrawnnot_applicable

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

NCT01791426

Clinical Trials (5)

Showing 5 of 5 trials
NCT04685109Not Applicable

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Active Not Recruiting
NCT04701086Not Applicable

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Completed
NCT02023268Phase 3

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Completed
NCT01568593Phase 3

Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome

Completed
NCT01791426Not Applicable

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5